In conclusion, as already indicated by Liu et al. [5], we propose that the combination of xCT immunotargeting with drugs that can restore the function of mut-p53 may be a new opportunity for the treatment of patients suffering from cancers that bear p53 mutations. This evidence concerns the gene TP53 and cancer.